Oncolytics Biotech (ONCY) Expected to Post Quarterly Earnings on Friday

Key Points

• Oncolytics Biotech is expected to report Q2 2026 results after market close on August 14, 2026, with analysts forecasting a loss of $0.0538 per share. The company previously reported a $0.08-per-share loss, missing consensus estimates by $0.03.
• ONCY shares opened at $0.80, near the lower end of their 52-week range of $0.73 to $1.51, while the company’s market capitalization stood at approximately $95.6 million.
• Analyst sentiment remains mixed but leans positive, with a consensus “Moderate Buy” rating and an average price target of $8.50. Institutional ownership is limited at 6.82%, and Oncolytics is advancing pelareorep, an investigational cancer therapy, through clinical trials.

Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) is anticipated to post its Q2 2026 results after the market closes on Friday, August 14th. Analysts expect the company to post earnings of ($0.0538) per share for the quarter. Interested persons can check the company's upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.03). On average, analysts expect Oncolytics Biotech to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Oncolytics Biotech Stock Up 0.4%

Shares of ONCY stock opened at $0.80 on Friday. The company has a 50 day moving average price of $0.87 and a 200-day moving average price of $0.94. Oncolytics Biotech has a 52 week low of $0.73 and a 52 week high of $1.51. The firm has a market capitalization of $95.55 million, a PE ratio of -2.58 and a beta of 1.13.

Institutional Investors Weigh In On Oncolytics Biotech

A number of large investors have recently made changes to their positions in ONCY. Scientech Research LLC bought a new position in shares of Oncolytics Biotech in the 3rd quarter worth approximately $25,000. Blair William & Co. IL bought a new stake in Oncolytics Biotech during the fourth quarter valued at approximately $28,000. Security National Bank of Sioux City Iowa IA bought a new stake in Oncolytics Biotech during the fourth quarter valued at approximately $29,000. CIBC Private Wealth Group LLC purchased a new stake in Oncolytics Biotech during the fourth quarter valued at approximately $44,000. Finally, Tocqueville Asset Management L.P. purchased a new stake in Oncolytics Biotech during the fourth quarter valued at approximately $63,000. 6.82% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ONCY. HC Wainwright restated a "buy" rating on shares of Oncolytics Biotech in a report on Tuesday, July 14th. Weiss Ratings upgraded shares of Oncolytics Biotech from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, July 13th. Finally, Wall Street Zen cut Oncolytics Biotech from a "hold" rating to a "sell" rating in a report on Saturday, May 16th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $8.50.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc NASDAQ: ONCY is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company's lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source